2012
DOI: 10.1590/s0004-27302012000800004
|View full text |Cite
|
Sign up to set email alerts
|

Hyperinsulinism/hyperammonemia (HI/HA) syndrome due to a mutation in the glutamate dehydrogenase gene

Abstract: SUMMARYThe hyperinsulinism/hyperammonemia (HI/HA) syndrome is a rare autosomal dominant disea se manifested by hypoglycemic symptoms triggered by fasting or highprotein meals, and by elevated serum ammonia. HI/HA is the second most common cause of hyperinsulinemic hypo glycemia of infancy, and it is caused by activating mutations in GLUD1, the gene that encodes mitochondrial enzyme glutamate dehydrogenase (GDH). Biochemical evaluation, as well as direct sequencing of exons and exonintron boundary regions of th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0
1

Year Published

2012
2012
2020
2020

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 16 publications
(20 reference statements)
0
4
0
1
Order By: Relevance
“…In treating hyperinsulinism-hyperammonemia syndrome (OMIM:606762), diazoxide inhibits insulin release and promotes complete resolution of hypoglycemia [42].…”
Section: Procedures To Mitigate Dominant Effect Of a Genetically Abnormentioning
confidence: 99%
“…In treating hyperinsulinism-hyperammonemia syndrome (OMIM:606762), diazoxide inhibits insulin release and promotes complete resolution of hypoglycemia [42].…”
Section: Procedures To Mitigate Dominant Effect Of a Genetically Abnormentioning
confidence: 99%
“…Miglustat is a form of substrate reduction therapy (SRT) used to treat Gaucher's disease (OMIM:230800) where miglustat inhibits the ceramide-specific glucosyltransferase which catalyses the first committed step of GSL synthesis [36]. Procedure to mitigate dominant effect of a genetically abnormal protein In treating hyperinsulinism-hyperammonemia syndrome (OMIM:606762), diazoxide inhibits insulin release and promotes complete resolution of hypoglycemia [37].…”
Section: Functional Complementation Of a Genetically Defective Proteimentioning
confidence: 99%
“…Patients with this syndrome will develop leucine-induced hypoglycaemia. Diazoxide is the treatment of choice for hyperinsulinism-hyperammonaemia syndrome [42,43].…”
Section: Congenital Hyperinsulinism Of Infancymentioning
confidence: 99%
“…U pacjentów z tym zespołem rozwinie się hipoglikemia indukowaną leucyną. Lekiem z wyboru w terapii zespołu hipoglikemia-hiperamonemia jest diazoksyd [42,43].…”
Section: Reviewunclassified